<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175341</url>
  </required_header>
  <id_info>
    <org_study_id>6222/22.03.2017</org_study_id>
    <nct_id>NCT03175341</nct_id>
  </id_info>
  <brief_title>Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer</brief_title>
  <official_title>Phase I/II Randomized Study to Evaluate the Role of Intravenous Ascorbic Acid Supplementation to Conventional Neoadjuvant Chemotherapy in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academic Emergency County Hospital Sibiu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU-UCL Namur (site Mont-Godinne), Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academic Emergency County Hospital Sibiu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forty years ago clinical studies conducted by Ewan Cameron and Linus Pauling suggested that
      intravenous (IV) and oral ascorbic acid (AA) may diminish symptoms and could improve survival
      in terminal cancer patients. Previous phase I and II clinical trials have found that high
      dose (1.5g/kg ) iv AA is well tolerated in cancer patients. This is a phase I/II, randomized
      study of parenteral administration of Ascorbic Acid (AA) as a supplement to the conventional
      neo-adjuvant chemotherapy in women with breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 5, 2017</start_date>
  <completion_date type="Anticipated">May 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single Blind (Participant)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>during the six months of neoadjuvant chemotherapy</time_frame>
    <description>Assessments are made through analysis of reported incidence of treatment-emergent Adverse Events. Toxicities (AEs) in both groups will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At baseline and each 28 days during the six months of neoadjuvant chemotherapy</time_frame>
    <description>The symptom checklist and the symptom related measures as defined by European Organization for Research and Treatment of Cancer (Questionnaire C30 and BR23) will be compared between arms using frequency tables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic efficacy</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Therapeutic efficacy assessed by Pathological response. Percentage of Participants Achieving Complete Response (CR) According to the Residual Cancer Burden score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>every 8 weeks, up to 6 months</time_frame>
    <description>Objective Response Rate using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of AA supplementation on serum inflammatory cytokine</measure>
    <time_frame>At baseline and every 8 weeks during the six months of neoadjuvant chemotherapy</time_frame>
    <description>Assessment of laboratory parameters including interleukin (IL)-6 and vascular endothelial growth factor (VEGF).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin C Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.
Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.
Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.</description>
    <arm_group_label>Vitamin C Supplement</arm_group_label>
    <other_name>Vitamin C</other_name>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>100 ml normal saline 0.9%</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>Saline 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status score ≤2;

          -  Diagnosed high-risk breast cancers (tumours ≥ 2cm and/or locally advanced breast
             tumors) and scheduled to receive neoadjuvant chemotherapy;

          -  Agree to avoid any additional supplemental ascorbic acid throughout the study;

          -  Normal glucose-6- phosphate dehydrogenase (G6PD) activity;

          -  Normal renal function (serum creatinine ≤ 1.2 mg/dl) and normal liver function;

          -  No evidence of urolithiasis;

          -  No evidence of chronic hemodialysis, iron overload (serum ferritin 500 ng/ml);

          -  Not pregnant or lactating women

        Exclusion Criteria:

          -  Important psychosomatic diseases or known gastrointestinal disorders (ulcer,
             gastritis, colitis, ileitis);

          -  Current smoking and/or alcohol consumption ≥ 3UI per day;

          -  Current use of the following drugs:

        Aspirin (exceeding 325 mg/day) Acetaminophen (exceeding 2 g/day) Glutathione Vitamin D
        (important doses)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florin Grosu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Academic Emergency County Hospital Sibiu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pop, MD</last_name>
    <phone>0040740551854</phone>
    <email>dr.florinpop@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Emergency County Hospital Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catalin Florin Pop, MD</last_name>
      <email>dr.florinpop@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Catalin Florin Pop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Maria Stanciu Pop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florin Grosu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academic Emergency County Hospital Sibiu</investigator_affiliation>
    <investigator_full_name>Pop Catalin Florin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>ascorbic acid</keyword>
  <keyword>vitamin C</keyword>
  <keyword>vitamin supplementation</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

